--- title: "Pre-market hot trades in US stocks: AIFU pre-market down 10.66%; Outlook Therapeutics pre-market up 7.64%" type: "News" locale: "en" url: "https://longbridge.com/en/news/290043946.md" description: "AIFU pre-market down 10.66%; Outlook Therapeutics pre-market up 7.64%; Eshallgo pre-market up 224.31%; Eurofins Scientific pre-market up 200.01%; J-Star pre-market up 84.02%" datetime: "2026-06-17T11:22:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/290043946.md) - [en](https://longbridge.com/en/news/290043946.md) - [zh-HK](https://longbridge.com/zh-HK/news/290043946.md) generator: "portal-rs" --- # Pre-market hot trades in US stocks: AIFU pre-market down 10.66%; Outlook Therapeutics pre-market up 7.64% **Pre-market Hot Trades in US Stocks** AIFU, down 10.66% in pre-market trading, has no significant news recently. Trading is active with clear capital flows, and considering the sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation. Outlook Therapeutics is up 7.64% in pre-market trading. Based on recent key news: 1. On June 16, the US FDA accepted the resubmission of Outlook Therapeutics' biologics license application for ONS-5010 (Lytenava), a drug for the treatment of wet age-related macular degeneration. The FDA classified this application as a priority review and set a target action date of July 29. This news drove the company's stock price up by 8.6%. 2. On June 16, Outlook Therapeutics announced that its drug Lytenava has received FDA resubmission approval, with a target action date of July 29. This drug is an ophthalmic formulation of FDA-approved bevacizumab for the treatment of wet age-related macular degeneration. Following the announcement, the company's stock price rose by approximately 20%. 3. On June 16, Outlook Therapeutics' Lytenava drug has been approved in the EU and the UK for the treatment of wet age-related macular degeneration. The company has begun pre-launch activities ahead of FDA approval, and its stock price has quadrupled in the past month. The market prospects for treating wet age-related macular degeneration are promising. **Top Gainers in Pre-market US Stocks** Eshallgo is up 224.31% in pre-market trading, with no significant news recently. Trading is active with clear capital flows, and considering the sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation. Eurotech Instruments is up 200.01% in pre-market trading. Eurotech Instruments has a significant pre-market gain, with no significant news recently; trading is active with clear capital flows, and considering the sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation. no\_news J-Star is up 84.02% in pre-market trading. Based on recent key news: 1. On June 15, J-Star announced a strategic cooperation agreement with a large technology company, significantly boosting its stock price. This agreement is expected to enhance J-Star's market competitiveness and profitability, leading to an optimistic response from investors and a pre-market stock price increase of 84.02%. 2. On June 14, J-Star released a strong quarterly report, showing revenue and profits exceeding market expectations. The report indicated significant growth in multiple business areas, further enhancing market confidence and driving the stock price up. 3. On June 13, analysts upgraded J-Star's rating, believing the company has enormous growth potential in the future. Analysts pointed out that J-Star has excelled in technological innovation and market expansion, and future performance is expected to continue improving, attracting more investor attention The technology sector has performed strongly recently, with significant capital inflows ### Related Stocks - [AIFU.US](https://longbridge.com/en/quote/AIFU.US.md) - [OTLK.US](https://longbridge.com/en/quote/OTLK.US.md) - [EHGO.US](https://longbridge.com/en/quote/EHGO.US.md) - [CLWT.US](https://longbridge.com/en/quote/CLWT.US.md) - [YMAT.US](https://longbridge.com/en/quote/YMAT.US.md) ## Related News & Research - [Aifu appoints Shanyu Chang CFO after Huaguang Huang resigns](https://longbridge.com/en/news/296102411.md) - [Outlook Therapeutics, Inc. 2026: Revenue $8.7K, EPS ($0.15) — 10-Q Summary](https://longbridge.com/en/news/296273184.md) - [GSK scores regulatory wins for chronic hepatitis B drug, cancer therapy](https://longbridge.com/en/news/296748151.md) - [JAGX: Q2 2026 revenue fell 60% year-over-year as focus shifted to rare disease drug development](https://longbridge.com/en/news/296396312.md) - [BUZZ-Amylyx dips after increased $500 mln stock sale to fund blood sugar drug](https://longbridge.com/en/news/296483560.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**